Immune Regulation News 10.22 June 15, 2018 | |
| |
TOP STORYScientists developed a CD4+ T cell-based adoptive immunotherapy protocol that was curative for mice with implanted colorectal tumors. By conducting metabolic profiling on tumors, they showed that adoptive immunotherapy profoundly altered tumor metabolism, resulting in glutathione depletion and accumulation of reactive oxygen species in tumor cells. [Cell Metab] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers showed that Bcl6-dependent control of follicular T cells is mediated by a complex formed between Bcl6 and the Mi-2β-nucleosome-remodeling deacetylase complex. Formation of this complex reflects the contribution of the intracellular isoform of osteopontin, which acts as a scaffold to stabilize binding between Bcl6 and the NuRD complex that together regulate the genetic program of both follicular helper T cells and follicular regulatory T cells. [Proc Natl Acad Sci USA] Abstract Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity The authors reveal a mechanism to selectively target and reprogram the function of tumor-infiltrating Tregs (TI-Tregs) by exploiting their dependency on the histone H3K27 methyltransferase enhancer of zeste homolog 2 (EZH2) in tumors. Disruption of EZH2 activity in Tregs, either pharmacologically or genetically, drove the acquisition of pro-inflammatory functions in TI-Tregs, remodeling the tumor microenvironment and enhancing the recruitment and function of CD8+ and CD4+ effector T cells that eliminate tumors. [Cell Rep] Full Article | Graphical Abstract Regulation of Thymocyte Trafficking by Tagap, a GAP Domain Protein Linked to Human Autoimmunity The authors showed in mice that Tagap-mediated signaling by the sema3E/plexin-D1 ligand-receptor complex attenuates thymocytes’ adhesion to the cortex through their β1-containing integrins. By promoting thymocyte detachment within the cortex of the thymus, Tagap-mediated signaling enabled their translocation to the medulla, which is required for continued thymic selection. [Sci Signal] Full Article Investigators found that although no mutations in the p110δ subunit have been detected thus far in breast cancer, the expression of p110δ becomes gradually elevated during human breast cancer progression from grade I to grade III. Pharmacological inactivation of p110δ in mice abrogated the formation of tumors and the recruitment of macrophages to tumor sites and strongly affected the survival, proliferation and apoptosis of grafted tumor cells. [Cell Death Dis] Full Article Researchers demonstrated that inhibition of mechanistic/mammalian target of rapamycin (mTOR) during T cell activation promoted the generation of long-lived central Tregs with a memory-like phenotype in mice. Metabolically, these central memory Tregs possess enhanced spare respiratory capacity, similar to CD8+ memory cells. [J Immunol] Abstract CK2 Controls Th17 and Regulatory T Cell Differentiation through Inhibition of FoxO1 Through use of a genetic approach to target CK2 kinase activity, investigators provide evidence of a major mechanism by which CK2 regulates the Th17/Treg axis through the inhibition of the transcription factor forkhead box protein O1 (FoxO1). [J Immunol] Abstract Lymph Node γδ and αβ CD8+ T Cells Share Migratory Properties Scientists characterized migratory behavior of endogenous αβ CD8+ and γδ T cells in lymph nodes by long-term tracking following in vivo photoconversion. They identified subsets of γδ T cells with distinct circulation kinetics that closely mirrored migratory subsets of αβ CD8+ T cells. [Sci Rep] Full Article The effects of IL15 secreted by gastric cancer mesenchymal stem cells on gastric cancer (GC) development were evaluated by detecting the stemness, epithelial-mesenchymal transition (EMT) and migration abilities of GC cell lines. [Stem Cells Dev] Abstract Galectin-7 (Gal-7) enhanced the proliferation of activated CD4+ T cells in a dose- and β-galactoside-dependent manner. Gal-7 treatment did not change the ratio of Th2 cells in activated CD4+ T cells, while it increased the ratio of Th1 cells. Gal-7 also induced activated CD4+ T cells to produce a higher level of IFN-γ and TNF-α and a lower level of IL-10. [Mol Immunol] Abstract Subscribe to our sister publications: Human Immunology News & Immunology of Infectious Disease News. | |
| |
REVIEWSTGF-β in T Cell Biology: Implications for Cancer Immunotherapy The authors review current advances in the understanding of the many roles of transforming growth factor beta (TGF-β) in T cell biology in the context of tumor immunity and discuss the possibility to manipulate TGF-β signaling to improve cancer immunotherapy. [Cancers (Basel)] Full Article Visit our reviews page to see a complete list of reviews in the immune regulation research field. | |
| |
INDUSTRY NEWSSeattle Children’s, with participating members Children’s National Health System, BC Children’s Hospital and Children’s Hospital Los Angeles, has launched CureWorks, an international collaborative of leading academic children’s hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer. CureWorks focuses on expanding immunotherapy trials and patient access around the world, as well as sharing data and collective expertise to advance novel cell therapies. [Seattle Children’s Hospital] Press Release Arcus Biosciences, Inc. announced that the FDA has cleared Investigational New Drug (IND) applications for the company’s two most advanced product candidates, AB928 and AB122. Clearance of the first IND for AB928 allows the Company to proceed with its planned Phase I/Ib trial to evaluate the safety, tolerability and preliminary efficacy of AB928 in combination with other agents, including AB122 and chemotherapy, in patients with breast and gynecologic malignancies. [Arcus Biosciences, Inc.] Press Release OncoMed Doses First Patient in Phase Ib Portion of Anti-TIGIT Clinical Trial OncoMed Pharmaceuticals Inc. announced that the first patient has been dosed in the company’s Phase Ib portion of the Phase Ia/Ib clinical trial of anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) in combination with anti-PD1. OncoMed’s anti-TIGIT candidate is an IgG1 monoclonal antibody checkpoint inhibitor which binds to the human TIGIT receptor on T-cells with a goal of improving the activation and effectiveness of T-cell and NK cell tumor-killing activity. [OncoMed Pharmaceuticals Inc.] Press Release | |
| |
POLICY NEWSNew Zealand Appoints First Female Chief Scientific Adviser The New Zealand government has appointed biochemist Juliet Gerrard as its next chief scientific adviser — the first woman to hold the position. [Nature News] Editorial Bill to Encourage Generic-Drug Development Passes a Key Hurdle A key Senate committee voted to advance legislation that aims to spur the development of new generic drugs and in turn, lower drug prices. [Stat News] Editorial Sexual Harassment Is Rife in the Sciences, Finds Landmark US Study Sexual harassment is pervasive throughout academic science in the United States, driving talented researchers out of the field and harming others’ careers, finds a report from the US National Academies of Sciences, Engineering, and Medicine in Washington DC. The analysis concludes that policies to fight the problem are ineffective because they are set up to protect institutions, not victims — and that universities, funding agencies, scientific societies and other organizations must take stronger action. [Nature News] Editorial North American Universities Increasingly Cancel Publisher Packages Florida State University (FSU) will head into negotiations with the publisher Elsevier to see how it can resolve a pricing issue. Back in April, FSU announced that it would not renew a so-called “big deal” with Elsevier in 2019, due to its “high and ever-increasing cost,” and would instead subscribe to a subset of the most-needed journals. [The Scientist] Editorial
| |
EVENTSNEW Keystone Symposia: Integrated Pathways of Disease in NASH and NAFLD Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW PhD Student – Cellular Immunotherapy (Glycostem Therapeutics) Research Technologist – Cell Separation (STEMCELL Technologies Inc.) Postdoctoral Research Fellow – Human Systems Immunology (University of Oslo) PhD Student Positions – Immunology (Multiple Locations) Postdoctoral Position – Immunology (Uppsala University) Postdoctoral Research Scientist – Immunology (Lilly) Postdoctoral Fellowship – Immunology (University of South Carolina) Postdoctoral Fellow – Immunology (Boston University School of Medicine) Postdoctoral Fellow – Innate Immune Signaling (Houston Methodist Research Institute) Postdoctoral Associate Position – Tumor Immunology/Immunotherapy (Duke Cancer Institute) Assistant, Associate, or Full Member – Cancer Immunology (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Immune Regulation News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|